Ishikawa J, Matsuura T, Nagai H, Kida K, Matsuda H, Murase M
Department of Pediatrics, School of Medicine, Ehime University.
Jpn J Antibiot. 1990 May;43(5):877-83.
We have investigated bioavailability, clinical efficacy, side effect and antimicrobial activity of norfloxacin (NFLX) to evaluate the efficacy and safety in the pediatric field. Results are summarized as follows 1. After oral administration of 100 mg, Tmax was 2 hours and T 1/2 were 4.2 and 2.6 hours in 2 cases. 2. In 10 cases of urinary tract infection (UTI) and 4 cases of intestinal tract infection (ITI), clinical efficacy rate was 100% (14/14). 3. In UTI, causative bacteria were all eradicated. In ITI, 1 case with Campylobacter jejuni remained unchanged. Overall eradication rate was 92.9% (13/14). 4. Antimicrobial activities to clinically isolated organisms such as Gram-negative rods or Staphylococcus aureus, MIC of NFLX was clearly superior to those of cefaclor, amoxicillin, nalidixic acid, fosfomycin and erythromycin. 5. Side effect of dipsia was observed in 1 case and eosinophilia was found in 1 case. But these reactions were mild and we were able to continue the administration of the drug. The above results suggest that NFLX is a useful and safe drug for the therapy of UTI and ITI in the pediatric field.
我们研究了诺氟沙星(NFLX)的生物利用度、临床疗效、副作用及抗菌活性,以评估其在儿科领域的疗效和安全性。结果总结如下:1. 口服100毫克后,2例患者的达峰时间(Tmax)为2小时,半衰期(T 1/2)分别为4.2小时和2.6小时。2. 在10例尿路感染(UTI)和4例肠道感染(ITI)患者中,临床有效率为100%(14/14)。3. 在UTI患者中,病原菌全部被清除。在ITI患者中,1例空肠弯曲菌感染患者病情未改善。总体清除率为92.9%(13/14)。4. 对临床分离的革兰氏阴性杆菌或金黄色葡萄球菌等病原菌,诺氟沙星的最低抑菌浓度(MIC)明显优于头孢克洛、阿莫西林、萘啶酸、磷霉素和红霉素。5. 观察到1例患者出现烦渴副作用,1例患者出现嗜酸性粒细胞增多。但这些反应较轻,我们能够继续给药。上述结果表明,诺氟沙星是治疗儿科领域UTI和ITI的一种有效且安全的药物。